Updating the ASC Relative Payment Weights for CY 2026 and Future Years We update the ASC relative payment weights each year using the national OPPS relative payment weights (and PFS nonfacility PE RVU-based amounts, as applicable) for that same calendar year and uniformly scale the ASC relative payment weights for each update year to make them budget neutral (72 FR 42533)
Use In Specific Populations Pregnancy Risk Summary Available data from cases reported in the published literature and postmarketing surveillance with CYANOKIT use in pregnant women are insufficient to identify a drug-associated risk for major birth defects, miscarriage, or adverse maternal and fetal outcomes
While it may not reverse advanced baldness, it shows great promise in slowing thinning, supporting regrowth in weakened follicles, and enhancing overall scalp health
The recent availability of Compound 21, the first orally active selective AT 2 receptor agonist, opens the possibility to explore whether AT 2 receptor stimulation could be a valuable concept for an innovative antihypertensive therapy
There is no approved formulation, no established PCOS dosing protocol, and the pharmacokinetics of subcutaneous versus IV delivery are still being refined
This presents a meaningful clinical concern, particularly in populations exposed to polypharmacy or managing complex comorbidities
